A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Describe Pharmacokinetics/Pharmacodynamics, and the Safety and of SPH3127 Tablet in Chinese Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 21 Jul 2017
At a glance
- Drugs SPH 3127 (Primary)
- Indications Hypertension
- Focus Adverse reactions
- Sponsors Shanghai Pharmaceuticals Holding
- 16 Jul 2017 Planned End Date changed from 1 Jul 2017 to 1 Jul 2018.
- 16 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Jun 2018.
- 02 May 2017 New trial record